Pot stocks start the week strongly: Here’s what you need to know

It has been a great start to the week for the Australian share market. In morning trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) is up a solid 0.7%.

Some of the biggest gains on the market today can be found in the medicinal cannabis industry. Here’s the current state of play in the fledgling industry:

The Auscann Group Holdings Ltd (ASX: AC8) share price has continued to climb higher, this time by 6% to 72 cents. Its shares have now rallied almost 25% since last week’s announcement that it has secured a licence to cultivate medicinal cannabis in Australia.

The Cann Group Ltd (ASX: CAN) share price has jumped 13% to 75 cents. Cann’s shares listed on the ASX last week at 30 cents. This means investors lucky enough to get in on the IPO have seen the value of their investment rise 150%. Cann was the first company in Australia to be granted a licence to cultivate medicinal cannabis.

The Creso Pharma Ltd (ASX: CPH) share price is up 9.5% to 64 cents. Creso Pharma became the first company to import medicinal cannabis products into Australia last week. Its subsidiary Health House will distribute its CanniMed products throughout the country.

The Hydroponics Company Ltd (ASX: THC) share price is flat at 36.5 cents. The Hydroponics Company was another pot stock to hit the ASX boards last week. It aims to be a leading manufacturer and distributer of cannabis products and equipment.

The MMJ Phytotech Ltd (ASX: MMJ) share price is up slightly to 41.5 cents. Today’s gain will be a welcome relief to shareholders. In the last 30 days MMJ Phytotech’s shares have been on a downward slide and fallen almost 35%.

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is up 5% to 6.3 cents. Last week the company announced a collaboration with the Royal Melbourne Institute of Technology. The two will work together on a full suite of medicinal cannabis research initiatives, initially centred on genetics and cultivation.

The Stemcell United Ltd (ASX: SCU) share price is up 7.5% to 14.5 cents today despite there being no news out of the company in the last couple of weeks. Its shares are amongst the most volatile in the industry with wild swings becoming an almost daily occurrence.

The Zelda Therapeutics Ltd (ASX: ZLD) share price is up 5% to 10 cents. Last month the company announced plans to expand its clinical trials in Chile to cover autism. If things go to plan Zelda could be generating revenues by next year.

Finally, although I think there are one or two companies amongst this growing list which could go on to bigger and brighter things, at this stage it is difficult to predict which will rise to the top. So for this reason I think investors may be better off just watching on from the sidelines for the time being.

So rather than risk your money in pot stocks I would suggest you take a look at these explosive growth shares instead. I'm tipping each of them for big things this year.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.